Youn H Kim (Stanford University, Stanford, CA, USA) presented results from MAVORIC, an open-label, international, randomised, phase 3 trial comparing mogamulizumab (an anti-chemokine receptor 4 antibody) with vorinostat in 372 patients with previously treated cutaneous T-cell lymphoma. Investigator-assessed progression-free survival (primary endpoint) was significantly longer with mogamulizumab than with vorinostat (median 7·7 months [95% CI 5·7–10·3] vs 3·1 months [2·9–4·1]; hazard ratio [HR] 0·53 [95% CI 0·41–0·69]; p<0·0001).

中文翻译：

---

2017 ASH会议

Youn H Kim（美国加利福尼亚州斯坦福的斯坦福大学）介绍了MAVORIC的结果，该药物是一项开放标签的国际性，随机，3期临床试验，该试验比较了莫加米珠单抗（抗趋化因子受体4抗体）与伏立诺他在372例先前接受过皮肤治疗的患者中的比较T细胞淋巴瘤。研究者评估的莫加莫珠单抗的无进展生存期（主要终点）显着长于伏立诺他（中位7·7个月[95％CI 5·7-10·3] vs 3·1个月[2·9-4·1] ]；危险比[HR] 0·53 [95％CI 0·41-0·69]； p <0·0001）。